Central nervous system involvement (Bing-Neel Syndrome) in patients with Waldenström macroglobulinemia

Click to increase image sizeClick to decrease image size

Disclosure statement

MAG: Dr. Gertz reports personal fees from Ionis/Akcea, personal fees from Prothena, personal fees from Sanofi, personal fees from Janssen, personal fees from Aptitude Health grants and personal fees from Ashfield Meetings personal fees from Juno, personal fees from Physicians Education Resource, personal fees for Data Safety Monitoring Board from Abbvie, fees from Johnson & Johnson, and Celgene, personal fees from Research to Practice, Meetings personal fees from Sorrento, Development of educational materials for i3Health. NCI SPORE MM SPORE 5P50 CA186781-04. TMM: Data Monitoring Committee: Seagen, Tess Therapeutics; Scientific Advisory Board: Eli Lilly & Co., Morpohsys, Incyte, Biegene, Loxo Oncology; Research Support to the LEO grant: Genentech, Sorrento. PK: Advisory board/consulting for BeiGene, Pharmacyclics, X4 Pharmaceuticals, Casma, Karyopharm, Sanofi, AbbVie, GSK; Research Grant: Amgen, Regeneron, BMS, Loxo, Ichnos, Karyopharm, Sanofi, AbbVie, GSK. The remaining authors have no relevant disclosures in relation to this work.

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.